Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
1994 1
1997 1
1999 1
2000 1
2001 2
2002 5
2003 5
2004 1
2005 3
2006 6
2007 6
2008 6
2009 4
2010 7
2011 5
2012 7
2013 5
2014 4
2015 2
2016 4
2017 13
2018 4
2019 10
2020 8
2021 16
2022 12
2023 5

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Results by year

Filters applied: . Clear all
Page 1
Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer.
Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Celestino J, Morgan MB, Nguyen TV, Conrads KA, Rangel KM, Dood RL, Hajek RA, Fawcett GL, Chu RA, Wilson K, Loffredo JL, Viollet C, Jazaeri AA, Dalgard CL, Mao X, Song X, Zhou M, Hood BL, Banskota N, Wilkerson MD, Te J, Soltis AR, Roman K, Dunn A, Cordover D, Eterovic AK, Liu J, Burks JK, Baggerly KA, Fleming ND, Lu KH, Westin SN, Coleman RL, Mills GB, Casablanca Y, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AK. Lee S, et al. Among authors: jazaeri aa. Cell Rep. 2020 Apr 14;31(2):107502. doi: 10.1016/j.celrep.2020.03.066. Cell Rep. 2020. PMID: 32294438 Free PMC article.
CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling.
Fix SM, Forget MA, Sakellariou-Thompson D, Wang Y, Griffiths TM, Lee M, Haymaker CL, Dominguez AL, Basar R, Reyes C, Kumar S, Meyer LA, Hwu P, Bernatchez C, Jazaeri AA. Fix SM, et al. Among authors: jazaeri aa. J Immunother Cancer. 2022 Jul;10(7):e003750. doi: 10.1136/jitc-2021-003750. J Immunother Cancer. 2022. PMID: 35882447 Free PMC article.
Immuno-Oncology for Gynecologic Malignancies.
How JA, Patel A, Jazaeri AA. How JA, et al. Among authors: jazaeri aa. Adv Exp Med Biol. 2021;1342:193-232. doi: 10.1007/978-3-030-79308-1_6. Adv Exp Med Biol. 2021. PMID: 34972966 Review.
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer.
Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim TB, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer LA, Sun CC, Sood AK, Coleman RL, Mills GB. Westin SN, et al. Among authors: jazaeri a. Clin Cancer Res. 2021 Dec 1;27(23):6354-6365. doi: 10.1158/1078-0432.CCR-21-1656. Epub 2021 Sep 13. Clin Cancer Res. 2021. PMID: 34518313 Free PMC article. Clinical Trial.
Immuno-oncology for Gynecologic Malignancies.
How J, Patel A, Jazaeri A. How J, et al. Among authors: jazaeri a. Adv Exp Med Biol. 2020;1244:149-182. doi: 10.1007/978-3-030-41008-7_7. Adv Exp Med Biol. 2020. PMID: 32301014 Review.
137 results